Literature DB >> 10664631

Cutaneous calciphylaxis. An underrecognized clinicopathologic entity.

L R Essary1, M R Wick.   

Abstract

Calciphylaxis (CPX), an uncommon syndrome characterized, in part, by progressive cutaneous vascular calcification, is seen principally in the setting of renal failure-associated hyperparathyroidism and is difficult to distinguish histologically from other microvasculopathies. We assessed histologic specimens from 13 cases of clinicopathologically classic CPX of the skin and reviewed documented histologic findings in the literature. Our series included 7 "early" and 6 "late" lesions (absence or presence of tissue necrosis, respectively). Histologically, early lesions were subtle and almost inapparent microscopically. Late lesions were easier to recognize because of obvious epidermal ulceration, dermal necrosis, and easily seen mural vascular calcification. The most common finding in both groups was acute and chronic calcifying septal panniculitis. Endovascular fibroblastic proliferation was more common in advanced lesions. Necrosis of dermal collagen was identified in only a few early lesions. Frank luminal vascular thrombosis was infrequent in both groups. The cited histologic findings largely were mirrored by those in the literature. Although they are relatively nonspecific when considered in isolation, the cited histopathologic features of cutaneous CPX allow for the diagnosis of this potentially lethal disorder when they are seen in combination with one another, particularly if detailed clinical data also are available.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10664631     DOI: 10.1309/AGLF-X21H-Y37W-50KL

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  26 in total

Review 1.  Unusual causes of cutaneous ulceration.

Authors:  Jaymie Panuncialman; Vincent Falanga
Journal:  Surg Clin North Am       Date:  2010-12       Impact factor: 2.741

2.  Case Report on Calciphylaxis: An Early Diagnosis and Treatment May Improve Outcome.

Authors:  Barbara J Marshall; Rachel E Johnson
Journal:  J Am Coll Clin Wound Spec       Date:  2013-11-12

3.  Calciphylaxis: evolving concepts.

Authors:  Giovanni Garini; Elisa Galletti; Roberto Ricci; Augusto Vaglio; Carlo Buzio
Journal:  Intern Emerg Med       Date:  2006       Impact factor: 3.397

4.  Quantifying a rare disease in administrative data: the example of calciphylaxis.

Authors:  Sagar U Nigwekar; Craig A Solid; Elizabeth Ankers; Rajeev Malhotra; William Eggert; Alexander Turchin; Ravi I Thadhani; Charles A Herzog
Journal:  J Gen Intern Med       Date:  2014-08       Impact factor: 5.128

Review 5.  Calciphylaxis: risk factors, diagnosis, and treatment.

Authors:  Sagar U Nigwekar; Daniela Kroshinsky; Rosalynn M Nazarian; Jeremy Goverman; Rajeev Malhotra; Vicki Ann Jackson; Mihir M Kamdar; David J R Steele; Ravi I Thadhani
Journal:  Am J Kidney Dis       Date:  2015-05-07       Impact factor: 8.860

Review 6.  Calciphylaxis: a review.

Authors:  Cynthia M Magro; Richard Simman; Sarah Jackson
Journal:  J Am Col Certif Wound Spec       Date:  2011-03-27

7.  Calciphylaxis in chronic renal failure: An approach to risk factors.

Authors:  W Rezaie; H A J M Overtoom; M Flens; R J L Klaassen
Journal:  Indian J Nephrol       Date:  2009-07

8.  Metal deposition in calcific uremic arteriolopathy.

Authors:  Lavanya Amuluru; Whitney High; Kim M Hiatt; James Ranville; Sudhir V Shah; Bilal Malik; Sundararaman Swaminathan
Journal:  J Am Acad Dermatol       Date:  2009-04-29       Impact factor: 11.527

9.  Successful treatment of calciphylaxis by a multidisciplinary approach.

Authors:  Lisa Borges; Pedro Rosa; Emanuel Dias; Isabel Cássio
Journal:  BMJ Case Rep       Date:  2014-07-17

10.  A fatal case of iatrogenic hypercalcemia after calcium channel blocker overdose.

Authors:  Michael T Sim; Frazier T Stevenson
Journal:  J Med Toxicol       Date:  2008-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.